Clinical Study
Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
Table 2
Demographics of patient cohorts.
| | No bevacizumab | Bevacizumab | Statistical significance of differences |
| | Histology | GBM 20 | GBM 19 | Not significant | | Gliosarcoma 1 | | Age (years) | 55 ± 9.3 | 58.7 ± 10.7 | Not significant | | Initial KPS | 70 (60–80) | 75 (65–85) | Not significant | | Time to first recurrence (months) | 9.25 ± 4.7 | 10.5 ± 4.8 | Not significant | | Mean time to diagnosis (from 1/1/05) | 25.9 ± 14.1 | 36.7 ± 8.8 | |
|
|
